NUCRYST Pharmaceuticals announces year-e...(commercialization of future products; ou...),Health

Date:2/14/2008

commercialization of future products; our cost reduction plans may not be sufficient to conserve cash and control expenses; competition from other silver-based pharmaceutical or medical device companies; our ability to raise additional financing required to fund further research and development, clinical studies and obtain regulatory approvals, on commercially acceptable terms or at all; our ability to protect our intellectual property rights and to not infringe on the intellectual property rights of others; our ability to comply with governmental regulations and standards; changes in general economic conditions; other risks and uncertainties unidentified at this time; management's response to these factors; and other factors described under "Risk Factors" in our Quarterly Report on 10-Q for the quarter ended September 30, 2007 and our Annual Report on Form 10-K for the year ended December 31, 2006, both of which have been filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities authorities in Canada at http://www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.

NUCRYST Pharmaceuticals Corp.

Consolidated Statements of Operations

(unaudited)

-------------------------------------------------------------------------

(thousands of U.S. Three Months Ended Twelve Months Ended

dollars except December 31 December 31

share and per ------------------------- -------------------------

share data) 2007 2006 2007 2006

-------------
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. NUCRYST Pharmaceuticals announces 2007 third quarter results
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST and Smith & Nephew Revise Agreements
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
8. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
9. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
10. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
11. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference